Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Lowered to Neutral at Cantor Fitzgerald

Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by stock analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a report released on Wednesday,Briefing.com Automated Import reports.

Several other brokerages have also issued reports on JAZZ. Robert W. Baird lifted their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Piper Sandler restated an “overweight” rating and set a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday. Needham & Company LLC raised their price target on shares of Jazz Pharmaceuticals from $205.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, Royal Bank of Canada cut their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $181.80.

Jazz Pharmaceuticals Trading Up 3.3 %

Shares of Jazz Pharmaceuticals stock traded up $4.55 during trading hours on Wednesday, hitting $144.22. The company’s stock had a trading volume of 1,787,968 shares, compared to its average volume of 669,349. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a 50 day moving average of $125.42 and a 200 day moving average of $118.44. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $148.06. The company has a market capitalization of $8.72 billion, a PE ratio of 20.25, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 5,053 shares of company stock worth $617,442 over the last three months. 4.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Fuller & Thaler Asset Management Inc. lifted its stake in Jazz Pharmaceuticals by 117.4% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock valued at $115,681,000 after buying an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $59,668,000. Dimensional Fund Advisors LP grew its stake in Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after purchasing an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock worth $225,076,000 after acquiring an additional 315,608 shares during the period. Finally, GMT Capital Corp boosted its stake in Jazz Pharmaceuticals by 140.0% during the 4th quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after purchasing an additional 296,800 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.